Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice.
暂无分享,去创建一个
P. Musiani | P. Lollini | G. Forni | P. Nanni | F. Cavallo | G. Nicoletti | E. Di Carlo | S. Wolf | E. Quaglino | S. Rovero | K. Boggio | E. Carlo | P. Lollini | Federica Cavallo | Stanley Wolf | G. Forni | Stefania Rovero
[1] P. Lollini,et al. Specific and nonspecific immunity in the prevention of spontaneous tumours. , 1999, Immunology today.
[2] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[3] P. Musiani,et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. , 1999, Cancer research.
[4] G. Trinchieri,et al. Immune Suppression by Recombinant Interleukin (rIL)-12 Involves Interferon γ Induction of Nitric Oxide Synthase 2 (iNOS) Activity: Inhibitors of NO Generation Reveal the Extent of rIL-12 Vaccine Adjuvant Effect , 1998, The Journal of experimental medicine.
[5] F. Balkwill,et al. IL‐12 regulates VEGF and MMPs in a murine breast cancer model , 1998, International journal of cancer.
[6] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[7] S. Pestka,et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.
[8] G. Bieler,et al. Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.
[9] J. Leonard,et al. Immunoregulation by interleukin‐12 in MB49.1 tumor‐bearing mice: Cellular and cytokine‐mediated effector mechanisms , 1997, European journal of immunology.
[10] Mihaela Skobe,et al. Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.
[11] G. Haas,et al. New developments in the use of cytokines for cancer therapy. , 1997, Anticancer research.
[12] P Signorelli,et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. , 1997, Journal of the National Cancer Institute.
[13] H. Fujiwara,et al. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. , 1997, Cancer research.
[14] K. McKenzie,et al. Breast cancer prevention strategies for the twentieth century , 1996 .
[15] L. Old,et al. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] H. Fujiwara,et al. Cellular and Molecular Mechanisms Underlying IL‐12‐Induced Tumor Regression , 1996, Annals of the New York Academy of Sciences.
[17] Albert R. Jonsen,et al. The advent of the ‘unpatients’ , 1996, Nature Medicine.
[18] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[19] J. Wigginton,et al. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. , 1996, Cancer research.
[20] J. Finke,et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. , 1996, Journal of immunology.
[21] R. Schreiber,et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.
[22] C. Garlanda,et al. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. , 1994, European journal of cell biology.
[23] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[24] P. Musiani,et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ‐interferon gene , 1993 .
[25] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[26] A. Villa,et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. , 1992, Cancer letters.
[27] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[28] H. Muller. Interleukin 12: A cytokine at the interface of inflammation and immunity , 1998 .
[29] K. McKenzie,et al. Breast cancer prevention strategies for the twenty-first century. , 1996, Molecular medicine today.
[30] C. Chiodoni,et al. Interferon (cid:103) –independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4 (cid:49) T Cells and Granulocyte/Macrophage Colony–stimulating Factor , 1998 .